Ricky Sun

Dr. Sun has served as a member of Savara’s Board of Directors since December 2019. Dr. Sun is a Managing Director at Bain Capital Life Sciences, LP and serves on the Board of Directors of Arcutis Biotherapeutics and Annexon Biosciences. Prior to joining Bain Capital, Dr. Sun was a Director of Corporate Development and Strategy at Biogen. Prior to Biogen, he was a Vice President at BlackRock as a member of the Fundamental Equity division of the Alpha Strategies Group and Senior Analyst for the fundamental large-cap growth equity team where he covered the healthcare sector. Prior to BlackRock, Dr. Sun was a Senior Healthcare Analyst at Citadel and Alyeska Investment Group. He also worked as a pharmaceutical Equity Research Analyst on Wall Street, spending time at Lehman Brothers and Morgan Stanley. He began his career as a Senior Scientist at Ironwood Pharmaceuticals, where he was involved in the discovery and development of Linzess, a drug for irritable bowel syndrome. Dr. Sun holds a Ph.D. in chemistry and chemical biology from Harvard University and was an NIH post-doctoral fellow in biological chemistry and molecular pharmacology at Harvard Medical School. He also received an M.B.A. from New York University Stern School of Business, where he was a Mildred Elperin Scholar. He graduated summa cum laude from Berea College with a B.A. in Chemistry.